Novel use of anifrolumab in a young patient with Jo-1-positive juvenile dermatomyositis.

Reliability of durometry to assess firmness of calcinosis lesions in Juvenile and adult dermatomyositis.

Relapse of Juvenile Dermatomyositis following Eight Years in Remission: A Case Report.

Severe Juvenile Dermatomyositis With Peripheral Nervous System Involvement: A Case Report.

Global landscape of juvenile dermatomyositis research: a bibliometric analysis.

Comprehensive Analysis Reveals Potential Molecular Targets in Juvenile Dermatomyositis.

Nailfold video capillaroscopy as a non-invasive biomarker in juvenile dermatomyositis: A longitudinal analysis of microvascular changes and clinical relevance over one year.

Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis.

Transition From Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype.

Interferon-Driven Tryptophan Metabolism Links Inflammation and Mental Health in Juvenile Dermatomyositis.

Presence of Multiple Muscle Specific Autoantibodies (MSAs) in a Young Child with Juvenile Dermatomyositis.

Lung Involvement in MDA5-Positive Juvenile Dermatomyositis: A Case of Misdiagnosed Pneumonia in a Toddler.

Clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseases.

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis.

Comparison of disease severity and activity between juvenile- and adult-onset dermatomyositis: a multicentre cohort study.

An Unusual Case of Juvenile Dermatomyositis Complicated by Macrophage Activation Syndrome.

Comparison of pre- and post-natal environmental exposures in United States versus Brazilian patients with juvenile dermatomyositis.

Sex Differences in PROMIS Pediatric Depressive Symptoms, Anxiety, and Psychological Stress Among Children and Adolescents Living With Pediatric Rheumatic Diseases.

Association of NXP2 autoantibodies with a more severe clinical phenotype of juvenile dermatomyositis.

Unmasking inflammation in juvenile dermatomyositis: myokine profiles of patients and bioengineered human muscle.

Rituximab for Early-Onset Juvenile Dermatomyositis Complicated by Interstitial Lung Disease.

A Comparative Bibliometric Analysis of Pediatric Interstitial Lung Disease Treatment: Global Trends, Advances, and Future Directions (2004-2024).

Juvenile dermatomyositis as a rare paraneoplastic manifestation of nasopharyngeal carcinoma.

Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes.

MDA5 Antibody Associated Juvenile Dermatomyositis Presenting as Rapidly Progressive Pulmonary Fibrosis-Case Report.

Predictive role of muscle MRI in juvenile dermatomyositis: A tertiary center experience.

Single-Cell Transcriptomics Reveals CCL3+ Classical Monocyte Subset Linked to Autoimmune Pathogenesis.

Neutrophil lymphocyte ratio as a marker of skin disease activity in older children with juvenile dermatomyositis.

Juvenile idiopathic inflammatory myopathies assessment by magnetic resonance imaging: a scoping review of protocols, scoring systems, and applications.

Intermittent Glucocorticoid Pulse Combined With Mycophenolate Mofetil in Juvenile Dermatomyositis.

Distinct cytokine signature in juvenile dermatomyositis: linking myositis-specific antibodies and clinical manifestations.

Juvenile dermatomyositis: new insights into pathogenesis and clinical applications.

[Clinical characteristics of juvenile dermatomyositis in anti-nuclear matrix protein 2 antibody-positive patients and risk factors for severity: a national multicenter retrospective study].

Superimposed Segmental Juvenile Dermatomyositis: A Case Report.

Toward a Treat-to-Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement?

Therapeutic plasma exchange in autoimmune diseases: a retrospective study in a tertiary pediatric hospital in Mexico.

Congruence Between Child Self-Reported and Caregiver-Proxy-Reported Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus.

Promising Treatments in Juvenile Dermatomyositis.

Physical Activity Monitors in Myositis: Bridging the Gap from Bedside to Clinical Trials.

Calcinosis in Adult and Juvenile Dermatomyositis: Pathogenesis and Potential Therapeutic Targets.

Diverse Joint Manifestations in Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis: A Unique Case Report.

Alternative polyadenylation and splicing regulation in refractory juvenile dermatomyositis: CELF2 at the crossroads.

IFN-α levels correlate with muscle disease activity only in juvenile dermatomyositis patients with anti-MDA5+ autoantibodies.

Neutrophil activation in juvenile dermatomyositis: associations with muscle function and disease progression.

Long-term outcomes of juvenile dermatomyositis.

Validation of the 2019 EULAR/ACR classification criteria and clinical characteristics of childhood-onset Japanese patients with systemic lupus erythematosus.

The effect of Rituximab on B cells in pediatric autoimmune rheumatic diseases.

Is Hydroxychloroquine Useful for the Treatment of Cutaneous Manifestations of Idiopathic Inflammatory Myopathies? A Systematic Review.

Impaired Brachial Artery Reactivity in Young Adults With Clinically Quiescent Juvenile Dermatomyositis.

PROMIS displays strong construct validity in pediatric and adult patients with idiopathic inflammatory myopathies.

[Relationship between common myositis-specific antibodies and clinical features in children with juvenile dermatomyositis].

Tumoral Calcinosis of the Knee With Secondary Infection in a Patient With Juvenile Dermatomyositis: Management Approach and Pathophysiological and Therapeutic Review.

Anti-TIF1-Gamma Autoantibodies-Positive Juvenile Dermatomyositis Associated With Interstitial Lung Disease: A Case Report.

Dazukibart for the treatment of severe TIF1γ-positive juvenile dermatomyositis.

Banker Type of Juvenile Dermatomyositis.

Discovery of tissue-specific proteomic signatures in juvenile dermatomyositis highlights pathways reflecting persistent disease activity, clinical heterogeneity, and myositis-specific autoantibody subtype.

Vitamin D Status in Paraguayan Children With Autoimmune Diseases.

A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era.

A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data.

[Clinical characteristics of anti-melanoma differentiation associated gene 5 antibody-positive juvenile dermatomyositis].

Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.

Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature.

Anasarca in Juvenile Dermatomyositis: An Uncommon Presentation.

Level of CD4+ central memory T cells and its clinical correlation in childhood-onset systemic lupus erythematosus.

Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review.

Application of HRCT-based radiomics to predict interstitial lung disease for juvenile dermatomyositis.

Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

CD68 + macrophage infiltrations in muscle tissue of juvenile dermatomyositis associated with the course of the disease, not with the severity.

Updates in juvenile dermatomyositis: pathogenesis and therapy.

Nailfold videocapillaroscopy in juvenile dermatomyositis: detailed correlations between microvascular abnormalities with clinical and laboratory parameters from an observational retrospective single-center study.

Transition of CELF2 PAS usage promotes recovery of refractory JDM through alternative splicing regulation of CTSB.

Juvenile dermatomyositis in Oman: clinical patterns and disease trajectory from a National cohort.

Anifrolumab in Refractory Juvenile Dermatomyositis.

Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC).

Forty-one Cytokine Profile and Interferon-I Score in Juvenile Dermatomyositis: A Case Series Study.

Panniculitis in Anti-MDA-5 Positive Juvenile Dermatomyositis: A Case Report.

Juvenile dermatomyositis: a severe and atypical presentation.

Efficacy of hydroxychloroquine treatment for the skin manifestations of juvenile dermatomyositis.

CAR T cell therapy for children with rheumatic disease: the time is now.

Epidemiology of Juvenile Dermatomyositis-What We Know and What More Is Needed?

Efficacy and safety of rhGH in juvenile dermatomyositis children with glucocorticoid-related growth failure.

Muscle Spatial Transcriptomic Reveals Heterogeneous Profiles in Juvenile Dermatomyositis and Persistence of Abnormal Signature After Remission.

Long-term outcome of juvenile dermatomyositis associated with lipodystrophy: experience of a University hospital.

A novel presentation of calcinosis cutis of the scalp in adult dermatomyositis.

Oral JAK inhibitors for pediatric inflammatory skin disease.

[Clinical analysis of 4 cases of juvenile dermatomyositis complicated with massive hemorrhage of digestive tract].

Anti-melanoma differentiation-associated gene 5 antibody associated rapidly progressive interstitial lung disease in a pediatric patient: a case report.

Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis.

Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis.

Rheumatologic manifestations in children with underlying inborn errors of immunity.

Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.

Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report.

Effect of graded nursing and feeding guidance based on water swallow test combined with enteral nutrition support in juvenile dermatomyositis children with swallowing dysfunction.

Exploring the Association of Sociodemographic Factors and Primary Diagnosis With Transition Readiness in Adolescents With Rheumatic Disease.

Juvenile Dermatomyositis.

Why Recommended Visit Intervals Should Be Extracted When Conducting Longitudinal Analyses Using Electronic Health Record Data: Examining Visit Mechanism and Sensitivity to Assessment Not at Random.

Effects of Juvenile Idiopathic Inflammatory Myopathies on Growth, Development, and Maturation: A Systematic Review and Metaanalysis.

Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.

Differences in Organ Damage Based on Age at Onset in Idiopathic Inflammatory Myopathies: A Retrospective Multicenter MYKO Study.

F18-FDG PET-CT Findings in Juvenile-Onset Polyarteritis Nodosa: A First Series and Literature Review.

Juvenile Dermatomyositis and Hepatitis B Viral Infection.

CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?

Juvenile Dermatomyositis Triggered by Influenza B: A Case Report on Viral-Induced Autoimmunity.

Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis.

Interferon Response Gene Score in Juvenile Dermatomyositis.

Cannabinoids in the management of refractory juvenile dermatomyositis: a patient's perspective.

Imaging assessment of calcinosis in juvenile dermatomyositis: a narrative review.

Tofacitinib: a promising agent for the treatment of persistent rashes in juvenile dermatomyositis.

Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1γ-positive juvenile dermatomyositis.

Juvenile Dermatomyositis in a Two-Year-Old Yemeni Girl in a Resource-Limited Setting: A Case Report.

Involving young people in research investigating comorbidity associated with childhood-onset rheumatic disease: perspectives of a series of focus groups.

Physical Growth Dynamics of Children With Juvenile Dermatomyositis.

A Case of Juvenile Dermatomyositis Presenting with Inverse Gottron's Papules: A Case Report.

Perspectives and experiences of parents of children with juvenile dermatomyositis: a semi-structured interview study.

Monozygotic twins discordant for juvenile dermatomyositis: clinical, serological and gene expression studies.

Imaging features of juvenile dermatomyositis complicated by pyomyositis in a 12-year-old boy: A case report.

Physical activity and quality of life of children and adolescents with juvenile idiopathic arthritis, juvenile systemic lupus erythematosus and juvenile dermatomyositis during the COVID-19 pandemic.

Type I interferon signature: a quantitative standardized method for clinical application.

Monoclonal antibody targeting IFNβ for the treatment of NXP2-positive ulcerative juvenile dermatomyositis.

Pseudoangioedema as a presenting symptom of dermatomyositis with antinuclear matrix protein 2 autoantibodies.

Correlation Between Interferon Response Gene Score and Disease Activity in Juvenile Dermatomyositis.

Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype.

Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis.

Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib.

Mortality in children and adolescents with autoimmune inflammatory rheumatic diseases admitted to the pediatric intensive care unit.

[A case of vedolizumab treatment for refractory juvenile dermatomyositis with secondary intestinal perforation].

Psychometric properties of patient-reported outcomes measurement information system (PROMIS) fixed short forms in Juvenile Myositis.

Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.

Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature.

Exploring the clinical profiles and management of juvenile dermatomyositis in Africa: a survey of African rheumatology care providers.

Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances.

The Role of Pyroptosis-Related Gene Signature and Immune Infiltration in Juvenile Dermatomyositis.

Safety and Efficacy of Long-term Use of Infliximab in Severe Juvenile Dermatomyositis - 12 Years of Follow-up.

Thromboembolic Risk in Juvenile Dermatomyositis Patients Treated With Intravenous Immunoglobulin.

Anti-MDA5 Positive Juvenile Dermatomyositis With Macrophage Activation Syndrome: A Case Report.

Juvenile Dermatomyositis Associated Cholestatic Liver Disease With Normal Creatine Kinase.

Unforeseen complication in juvenile dermatomyositis.

Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis.

The value of quantitative muscle ultrasound in monitoring muscle and fascia inflammatory activity in juvenile dermatomyositis patients.

Radiographs in Pediatric Rheumatology: Where Do We Stand?

Transient negativity for the anti-TIF1γ antibody before treatment in juvenile dermatomyositis.

A Bayesian latent class approach to causal inference with longitudinal data.

Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review.

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges.

Case Report: IVIG causing bilateral papilledema and increased intracranial hypertension in patients with anti-TIF-1γ antibody-positive JDM.

Anasarca and Systemic Capillary Leak Syndrome as an Unusual Presentation of Juvenile Dermatomyositis: Report of Three Cases and Case-Based Review.

Anti-lipoprotein lipase antibodies: A review.

Calcinosis universalis in juvenile dermatomyositis.

Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy.

Anesthetic Challenges in Laparoscopic Surgery for a Child with Juvenile Dermatomyositis.

Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies.

Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review.

Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis.

Rituximab Treatment in Adult Patients With Idiopathic Inflammatory Myositis: A Systematic Review and Meta-analysis.

Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis.

Dyslipidemia in Juvenile Dermatomyositis.

Ringing in the Patient Voice: Measuring Patients' Lived Experience of Dermatomyositis Symptoms.

Genome-wide identification of cell type-specific susceptibility genes for Juvenile dermatomyositis through the analysis of N6-methyladenosine-associated SNPs.

Interferon-β-Induced Injury During Pediatric Muscle Differentiation: Insight Into Juvenile Dermatomyositis Pathogenesis.

Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.

Epidemiological Characteristics of Patients With Juvenile Dermatomyositis in China: A Multicenter Study.

Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study.

Penicillamine-Induced Juvenile Dermatomyositis: A Rare Clinical Encounter.

Rare skin manifestation of juvenile dermatomyositis: peri-orbital oedema and facial swelling.

Nailfold Capillaroscopy Changes in Patients with Idiopathic Inflammatory Myopathies.

Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.

Profile of patients with Juvenile Dermatomyositis and Anti-MDA5 autoantibodies.

14-month-old female with anti-MDA5 juvenile dermatomyositis complicated by liver disease: a case report.

Juvenile Dermatomyositis: Diagnosis and Management.

Mining for Gems: Early Detection of Calcinosis in Juvenile Dermatomyositis Using Low-Dose Computed Tomography.

Double-negative T cells in pediatric rheumatic diseases.

The influence of environmental factors related to Juvenile Dermatomyositis (JDM), its course and refractoriness to treatment.

Cutaneous Ulcers and Response to Treatment in a Child with Anti-MDA5 Dermatomyositis.

Atherosclerotic cardiovascular disease following a diagnosis of idiopathic inflammatory myopathy: analysis from a retrospective cohort in the TriNetX registry.

Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice.

Paraneoplastic dermatomyositis and Hodgkin's lymphoma in a 14-year-old girl: a case report and literature review.

Prevalence and Clinical Implications of Autoantibodies in Juvenile Dermatomyositis: A Single-Center Experience From India.

Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies.

Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.

Calcinosis in dermatomyositis.

Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis.

Assay for interferon gamma release as a novel marker in pediatric patients with systemic lupus erythematosus.

Decoding the genetic landscape of juvenile dermatomyositis: insights from phosphorylation-associated single nucleotide polymorphisms.

Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis.

Over Activation of IL-6/STAT3 Signaling Pathway in Juvenile Dermatomyositis.

Juvenile dermatomyositis complications: navigating gastrointestinal perforations and treatment challenges, a case report.

Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry.

Capillaroscopy in the daily clinic of the pediatric rheumatologist.

An Adolescent Case of Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis With Interstitial Lung Disease Successfully Treated by Multitarget Therapy Avoiding Cyclophosphamide: A Case Report and Literature Review.

Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children.

The Diagnostic Role of Skin Manifestations in Rheumatic Diseases in Children: A Critical Review of Paediatric Vasculitis.

Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness.

Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis.

Undercover lung damage in pediatrics - a hot spot in morbidity caused by collagenoses.

Increased percentage of HLA-DR T cells in untreated juvenile dermatomyositis.

Case Report: Contiguous presentation of anti-MDA5 juvenile dermatomyositis and anti-AQP4 neuromyelitis optica spectrum disorder in an adolescent patient.

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.

Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis.